Bsense Announces Positive Topline Proof-of-Concept
NESS ZIONA, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bsense Bio Therapeutics Ltd., a FutuRx portfolio biopharmaceutical company dedicated to developing...
Source: globenewswire.com
Orbimed Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Orbimed Partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Orbimed Partners Today - Breaking & Trending Today
Biotechs are Getting Routed to Close the Year
The rapid development and production of Covid vaccines sent biotech stocks to new heights last year, especially with shares in BioNTech and Moderna...
Source: fool.com
Biotechs are Getting Routed to Close the Year
The rapid development and production of Covid vaccines sent biotech stocks to new heights last year, especially with shares in BioNTech and Moderna...
Source: fool.com
Atomwise Announces Growing Portfolio of Joint Venture Companies
Published: Dec 21, 2020 Dec. 21, 2020 21:37 UTC Atomwise unveils a growing portfolio of emerging joint venture companies, with programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Atomwise CEO and joint venture companies are scheduled to speak at Informa's Biotech Showcase from January 11-15, 2021 during J.P. Morgan Healthcare Week. Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, today unveiled its growing portfolio of emerging joint venture companies with research programs spanning oncology, immunol...
Source: biospace.com
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority
(1) A2i Therapeutics secures seed funding from FutuRx and its investors Johnson Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority to develop novel small molecule immuno-oncology agents. Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise's AtomNet platform for ...
Source: finanznachrichten.de